MicroRNAs and drug resistance in colorectal cancer with special focus on 5-fluorouracil.
Fahima Danesh PouyaMaria GazouliYousef RasmiDimitra Ioanna LampropoulouMohadeseh NematiPublished in: Molecular biology reports (2022)
Colorectal cancer is globally one of the most common cancers in all age groups. The current chemotherapy combinations for colorectal cancer treatment include 5-fluorouracil-based regimens; however, drug resistance remains one of the main reasons for chemotherapy failure and disease recurrence. Many studies have determined colorectal cancer chemoresistance mechanisms such as drug efflux, cell cycle arrest, DNA damage repair, apoptosis, autophagy, vital enzymes, epigenetic, epithelial-mesenchymal transition, stem cells, and immune system suppression. Several microRNAs affect drug resistance by regulating the drug resistance-related target genes in colorectal cancer. These drug resistance-related miRNAs may be used as promising biomarkers for predicting drug response or as potential therapeutic targets for treating patients with colorectal cancer. This work reviews and discuss the role of selected microRNAs in 5-fluorouracil resistance and their molecular mechanisms in colorectal cancer.
Keyphrases
- cell cycle arrest
- stem cells
- cell death
- dna damage
- epithelial mesenchymal transition
- oxidative stress
- gene expression
- endoplasmic reticulum stress
- signaling pathway
- dna methylation
- systematic review
- risk assessment
- drug induced
- human health
- rectal cancer
- transcription factor
- electronic health record
- genome wide identification